Loading...
XTAI
4142
Market cap243mUSD
Jun 13, Last price  
17.05TWD
1D
-2.01%
1Q
-22.32%
Jan 2017
-21.40%
IPO
-53.95%
Name

Adimmune Corp

Chart & Performance

D1W1MN
XTAI:4142 chart
No data to show
P/E
—
P/S
4.62
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.18%
Rev. gr., 5y
3.68%
Revenues
1.56b
-12.78%
1,369,929,000834,775,000290,363,000387,162,000414,093,000480,506,000290,737,000606,725,000562,743,000822,366,0001,299,689,0001,869,147,0001,641,061,0002,251,624,0001,785,094,0001,556,989,000
Net income
-243m
L-62.06%
588,882,000161,307,000-471,318,000-603,680,000-600,453,000-614,422,000-761,087,000-595,352,000-760,176,000-609,117,000-321,737,0001,241,246,00028,378,000146,216,000-639,891,000-242,750,000
CFO
668m
P
600,423,000516,393,000-293,775,000-409,475,000-568,636,000-417,354,000-373,817,000-773,530,0006,874,000-601,740,000-261,703,0002,321,723,000-480,517,000-291,965,000-892,349,000668,481,000
Dividend
Sep 14, 20210.5 TWD/sh
Earnings
Jun 20, 2025

Profile

Adimmune Corporation manufactures and sells human vaccines in Taiwan. It offers AdimFlu-S, a quadrivalent influenza vaccine; tetanus toxoid alum precipitated product that is used for the prevention of tetanus after injury; Japanese encephalitis vaccines; Trivalent influenza vaccines; Quadrivalent influenza vaccine; Influenza A (H1N1) Virus Monovalent Vaccine; Tetanus Toxoid; and purified Tuberculin, as well as contract manufacturing services. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001. Adimmune Corporation was founded in 1965 and is headquartered in Taichung, Taiwan.
URL
https://www.adimmune.com.tw/
IPO date
Sep 29, 2010
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,556,989
-12.78%
1,785,094
-20.72%
2,251,624
37.21%
Cost of revenue
1,856,080
2,113,965
2,153,071
Unusual Expense (Income)
NOPBT
(299,091)
(328,871)
98,553
NOPBT Margin
4.38%
Operating Taxes
10,000
Tax Rate
10.15%
NOPAT
(299,091)
(328,871)
88,553
Net income
(242,750)
-62.06%
(639,891)
-537.63%
146,216
415.24%
Dividends
Dividend yield
Proceeds from repurchase of equity
(17,545)
(17,264)
(309,802)
BB yield
0.21%
0.12%
2.03%
Debt
Debt current
839,121
1,224,641
161,712
Long-term debt
1,828,960
1,981,404
2,179,198
Deferred revenue
Other long-term liabilities
838
1,937
2,351
Net debt
208,781
638,625
(620,020)
Cash flow
Cash from operating activities
668,481
(892,349)
(291,965)
CAPEX
(154,193)
(221,457)
(419,625)
Cash from investing activities
(310,899)
(366,563)
(322,066)
Cash from financing activities
(478,802)
859,296
823,194
FCF
332,261
(772,476)
(629,641)
Balance
Cash
2,472,127
2,485,008
2,972,590
Long term investments
(12,827)
82,412
(11,660)
Excess cash
2,381,451
2,478,165
2,848,349
Stockholders' equity
4,829,457
5,234,698
5,988,315
Invested Capital
5,777,813
6,443,968
5,961,408
ROIC
1.61%
ROCE
1.12%
EV
Common stock shares outstanding
424,671
421,508
427,679
Price
20.10
-39.37%
33.15
-6.88%
35.60
-20.27%
Market cap
8,535,886
-38.91%
13,972,990
-8.23%
15,225,372
-20.63%
EV
9,073,637
14,914,681
15,026,417
EBITDA
(83,393)
(104,746)
357,869
EV/EBITDA
41.99
Interest
36,487
33,426
22,592
Interest/NOPBT
22.92%